Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)
Year: 2020
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Joselle Cook, Kah-Whye Peng, Brenda F Ginos, Amylou C. Dueck, Marissa Giers, Nandakumar Packiriswamy, Beth Brunton, Mrinal M. Patnaik, Thomas E. Witzig, Francis K. Buadi, Angela Dispenzieri, Morie A Gertz, Ronald S. Go, Suzanne R. Hayman, John A. Lust, David Dingli, S. Vincent Rajkumar, Nelson Leung, Rahma M Warsame, Wilson I Gonsalves, Taxiarchis Kourelis, Eli Muchtar, P. Leif Bergsagel, Stephen Broski, Prashant Kapoor, Robert A. Kyle, Mustaqeem A. Siddiqui, Amie Fonder, Miriam A. Hobbs, Yi L. Hwa, Yi Lin, Shaji K. Kumar, Stephen J. Russell, Martha Q. Lacy
Institutions: Mayo Clinic, Mayo Clinic in Arizona
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2907790623